CVS Health Co. (NYSE:CVS) Stock Holdings Lessened by Hancock Whitney Corp

Hancock Whitney Corp decreased its holdings in shares of CVS Health Co. (NYSE:CVS) by 1.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,730 shares of the pharmacy operator’s stock after selling 221 shares during the quarter. Hancock Whitney Corp’s holdings in CVS Health were worth $800,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Pzena Investment Management LLC grew its stake in CVS Health by 132.9% during the 2nd quarter. Pzena Investment Management LLC now owns 12,936,388 shares of the pharmacy operator’s stock worth $764,023,000 after buying an additional 7,382,931 shares during the last quarter. Pathway Financial Advisers LLC increased its holdings in shares of CVS Health by 5,864.2% in the 3rd quarter. Pathway Financial Advisers LLC now owns 1,730,343 shares of the pharmacy operator’s stock worth $108,804,000 after acquiring an additional 1,701,331 shares during the period. State of Michigan Retirement System boosted its stake in CVS Health by 402.5% during the 2nd quarter. State of Michigan Retirement System now owns 2,005,677 shares of the pharmacy operator’s stock valued at $118,455,000 after purchasing an additional 1,606,500 shares during the period. Swedbank AB bought a new position in CVS Health in the 1st quarter worth about $110,816,000. Finally, AQR Capital Management LLC increased its stake in shares of CVS Health by 33.5% in the second quarter. AQR Capital Management LLC now owns 5,289,788 shares of the pharmacy operator’s stock valued at $310,722,000 after purchasing an additional 1,327,855 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 1.8 %

CVS Health stock opened at $59.02 on Wednesday. The stock has a market cap of $74.27 billion, a P/E ratio of 14.98, a P/E/G ratio of 1.01 and a beta of 0.55. CVS Health Co. has a 12 month low of $52.71 and a 12 month high of $83.25. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The company’s fifty day simple moving average is $59.26 and its 200-day simple moving average is $58.69.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.01. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The business had revenue of $95.43 billion during the quarter, compared to analyst estimates of $92.72 billion. During the same period in the previous year, the company earned $2.21 EPS. The firm’s revenue was up 6.3% on a year-over-year basis. As a group, sell-side analysts forecast that CVS Health Co. will post 5.43 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Monday, October 21st were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 4.51%. The ex-dividend date was Monday, October 21st. CVS Health’s dividend payout ratio is presently 67.51%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Barclays cut their target price on CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. Truist Financial reiterated a “buy” rating and issued a $67.00 target price (down previously from $76.00) on shares of CVS Health in a research report on Wednesday, November 20th. Cantor Fitzgerald restated a “neutral” rating and set a $62.00 price target on shares of CVS Health in a research report on Tuesday, October 1st. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of CVS Health from $64.00 to $63.00 and set a “hold” rating for the company in a report on Friday, August 9th. Finally, Royal Bank of Canada cut their target price on CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $70.33.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.